Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Talazoparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TALAPRO-2
- Sponsors Pfizer
- 27 Jan 2024 Results of exploratory biomarker analyses assessing HRR gene subgroups and potential associations with secondary efficacy endpoints in pts with HRRm tumors, presented at the 2024 Genitourinary Cancers Symposium
- 08 Jan 2024 According to a Pfizer media release, based on this study, the European Commission (EC) has approved talazoparib in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. This approval in all 27 EU member states plus Iceland, Liechtenstein, and Norway.
- 01 Jan 2024 Results for radiographic progression-free survival and safety, published in the Nature Medicine